Results 181 to 190 of about 8,252,790 (324)
Trends, lag and characteristics of rare disease drug approval in the USA and China, 1983-2022. [PDF]
Wang S +11 more
europepmc +1 more source
Letter comments on: "Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'". [PDF]
Müller B, Estay R.
europepmc +1 more source
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis +20 more
wiley +1 more source
‘Civil society involvement in drug policy’ webinar.
On 30th November 2018, Ana Liffey Drug Project hosted a webinar about Civil Society Involvement in Drug Policy. The event included interviews with: Anna Quigley (CityWide) Tony Duffin (Ana Liffey Drug Project) Aoife Frances (National Family Support ...
core
Response to "Anticancer Drug Approval in China: From Acceleration of Access to Certainty of Benefits". [PDF]
Fu L, Cui Y.
europepmc +1 more source
Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot. [PDF]
Matthew-Onabanjo AN +10 more
europepmc +1 more source
Versatile vector tools for efficient protein screening across multiple expression systems
A unified vector toolkit enables rapid protein expression screening across E. coli, insect, and mammalian cells. A single primer pair amplifies the target gene, which is inserted into any vector via a standardized interface. This streamlined workflow eliminates repeated cloning steps, accelerating the identification of optimal expression conditions for
Zhimin Zhu +5 more
wiley +1 more source
Training toolkit on drug policy advocacy.
This training toolkit has been developed by the International Drug Policy Consortium (IDPC) and the Eurasian Harm Reduction Network (EHRN) to build the capacity of civil society organisations for engaging with, and influencing, drug policy making ...
core

